The purpose of this application is to continue the involvement of the University of Pennsylvania as a site for the NET-PD large, simple trial of creatine (LS-1). It is well-known that there is a great need for treatments that can slow progression in degenerative disorders such as Parkinson's Disease. The goal of the LS-1 trial is to test the hypothesis that daily administration of creatine (10gm/day) is more effective than placebo in slowing clinical decline in PD between baseline and the 5 year follow-up visit in the context of a large, simple trial. The University of Pennsylvania has participated in the NET-PD consortium since its inception. In the upcoming funding cycle, we propose to continue our role as an active, successful recruiting site and a participant in the intellectual activities related t the study including review of data and participation in manuscript preparation.

Public Health Relevance

The accumulated disability that PD causes is a major source of diminished quality of life and increased health care costs. Despite the advances in our understanding of the pathophysiology in PD, there are no current therapies that slow the inexorable clinical decline. LSI will help to determine if creatine can slow clinical decline and provide better information on the course of early PD than is currently available.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10NS044451-11
Application #
8460674
Study Section
Special Emphasis Panel (ZNS1-SRB-B (34))
Program Officer
Moy, Claudia S
Project Start
2002-09-30
Project End
2015-11-30
Budget Start
2013-01-01
Budget End
2013-11-30
Support Year
11
Fiscal Year
2013
Total Cost
$97,240
Indirect Cost
$36,465
Name
University of Pennsylvania
Department
Neurology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Siderowf, A; Xie, S X; Hurtig, H et al. (2010) CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology 75:1055-61
Hu, W T; Chen-Plotkin, A; Grossman, M et al. (2010) Novel CSF biomarkers for frontotemporal lobar degenerations. Neurology 75:2079-86
Hoops, S; Nazem, S; Siderowf, A D et al. (2009) Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 73:1738-45
Mauldin, Patrick D; Guimaraes, Paulo; Albin, Roger L et al. (2008) Optimal frequency for measuring health care resource utilization in Parkinson's disease using participant recall: the FS-TOO resource utilization substudy. Clin Ther 30:1553-7